Show simple item record

dc.creatorRojas-Villarraga, Adriana 
dc.creatorTorres-Gonzalez, July-Vianneth 
dc.creatorRuiz-Sternberg, Angela María 
dc.date.accessioned2020-04-23T18:05:15Z
dc.date.available2020-04-23T18:05:15Z
dc.date.created2014
dc.date.issued2014
dc.identifier.issn1932-6203
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/21750
dc.description.abstractBackground: There is conflicting data regarding exogenous sex hormones [oral contraceptives (OC) and hormonal replacement therapy (HRT)] exposure and different outcomes on Systemic Lupus Erythematosus (SLE). The aim of this work is to determine, through a systematic review and meta-analysis the risks associated with estrogen use for women with SLE as well as the association of estrogen with developing SLE. Methods and Findings: MEDLINE, EMBASE, SciElo, BIREME and the Cochrane library (1982 to July 2012), were databases from which were selected and reviewed (PRISMA guidelines) randomized controlled trials, cross-sectional, case-control and prospective or retrospective nonrandomized, comparative studies without language restrictions. Those were evaluated by two investigators who extracted information on study characteristics, outcomes of interest, risk of bias and summarized strength of evidence. A total of 6,879 articles were identified; 20 full-text articles were included. Thirty-two meta-analyses were developed. A significant association between HRT exposure (Random model) and an increased risk of developing SLE was found (Rate Ratio: 1.96; 95%-CI: 1.51-2.56; P-value<0.001). One of eleven meta-analyses evaluating the risk for SLE associated with OC exposure had a marginally significant result. There were no associations between HRT or OC exposure and specific outcomes of SLE. It was not always possible to Meta-analyze all the available data. There was a wide heterogeneity of SLE outcome measurements and estrogen therapy administration. Conclusion: An association between HRT exposure and SLE causality was observed. No association was found when analyzing the risk for SLE among OC users, however since women with high disease activity/Thromboses or antiphospholipid-antibodies were excluded from most of the studies, caution should be exercised in interpreting the present results. To identify risk factors that predispose healthy individuals to the development of SLE who are planning to start HRT or OC is suggested. © 2014 Rojas-Villarraga et al.
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.relation.ispartofPLoS ONE, ISSN: 1932-6203 Vol. 9, No. 8 (2014)
dc.relation.urihttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0104303&type=printable
dc.subject.ddcEnfermedades 
dc.titleSafety of hormonal replacement therapy and oral contraceptives in systemic lupus erythematosus : A systematic review and meta-analysis
dc.typereview
dc.subject.keywordPhospholipid antibody
dc.subject.keywordOral contraceptive agent
dc.subject.keywordCase control study
dc.subject.keywordComparative study
dc.subject.keywordCross-sectional study
dc.subject.keywordDisease activity
dc.subject.keywordDisease association
dc.subject.keywordDisease predisposition
dc.subject.keywordDrug contraindication
dc.subject.keywordDrug efficacy
dc.subject.keywordDrug exposure
dc.subject.keywordDrug safety
dc.subject.keywordEffect size
dc.subject.keywordEstrogen therapy
dc.subject.keywordEvidence based medicine
dc.subject.keywordHormone substitution
dc.subject.keywordHuman
dc.subject.keywordMenopausal syndrome
dc.subject.keywordMeta analysis
dc.subject.keywordOral contraceptive use
dc.subject.keywordOutcome assessment
dc.subject.keywordProspective study
dc.subject.keywordRandomized controlled trial (topic)
dc.subject.keywordRetrospective study
dc.subject.keywordreview
dc.subject.keywordRisk assessment
dc.subject.keywordRisk benefit analysis
dc.subject.keywordRisk factor
dc.subject.keywordSensitivity analysis
dc.subject.keywordSystematic review
dc.subject.keywordSystemic lupus erythematosus
dc.subject.keywordThrombosis
dc.subject.keywordAdult
dc.subject.keywordChemically induced
dc.subject.keywordEstrogen therapy
dc.subject.keywordFemale
dc.subject.keywordInfertility, Female
dc.subject.keywordLupus Erythematosus, Systemic
dc.subject.keywordMiddle aged
dc.subject.keywordPathology
dc.subject.keywordRisk
dc.subject.keywordAdult
dc.subject.keywordCase-Control Studies
dc.subject.keywordContraceptives, Oral
dc.subject.keywordEstrogen Replacement Therapy
dc.subject.keywordEstrogens
dc.subject.keywordFemale
dc.subject.keywordHumans
dc.subject.keywordInfertility, Female
dc.subject.keywordMiddle Aged
dc.subject.keywordOdds Ratio
dc.subject.keywordProspective Studies
dc.subject.keywordRetrospective Studies
dc.subject.keywordRisk
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.type.spaRevisión
dc.rights.accesoAbierto (Texto Completo)
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.creator.googleRojas-Villarraga, A.
dc.creator.googleTorres-Gonzalez, J.-V.
dc.creator.googleRuiz-Sternberg, Á.-M.
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0104303
dc.relation.citationIssueNo. 8
dc.relation.citationTitlePLoS ONE
dc.relation.citationVolumeVol. 9


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record